News

Wave Is Developing Two Drugs That Target a Common ALS Mutation

Wave Life Sciences is developing two ALS and frontotemporal dementia therapies that target a gene mutation common in both. The therapies target mutations of the C9orf72 gene, Wave said in a business update. “I am excited to announce our next development program targeting C9orf72 mutations in ALS and FTD,” Dr.

Perceptive Devices and Tobii Dynavox Partnership Will Combine Facial Expression and Eye Tracking Technology

Perceptive Devices, a company specializing in hands-free and voice-free electronic devices, is partnering with eye tracking device maker Tobii Dynavox to develop a new generation of hands-free and voice-free control technology for those with physical disabilities. Users of Tobii Dynavox products will now have the option of controlling their devices with Perceptive…